UGT2B15 and benign prostatic hyperplasia: Consequently, UGT2B15 is implicated in diseases associated with androgen imbalances, and modulating its activity could help regulate androgen levels and improve outcomes in conditions such as benign prostatic hyperplasia (BPH), prostate cancer, and other androgen-dependent diseases [28, 29].